Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
- PMID: 35042011
- DOI: 10.1016/j.jtct.2022.01.009
Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
Abstract
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized post-transplantation complication, yet the overall incidence of the disease remains under debate. To determine the pooled incidence of TA-TMA in a systematic review of literature and to identify consistent risk factors. We performed a systematic review using the MEDLINE, Embase, and CENTRAL databases to identify cohort studies that reported incidence of and risk factors for TA-TMA from 2004 to 2020. We conducted a meta-analysis of proportion to estimate the pooled incidence of TA-TMA using a random-effects model. We assessed moderators of heterogeneity through subgroup analysis, risk of bias through ROBINS-I, and publication bias through funnel plot. Among 21 cohort studies with a total of 36,163 adult and pediatric patients who underwent allogeneic transplantation, the pooled incidence of TA-TMA was 12% (95% confidence interval, 9% to 16%). The diagnostic criteria used to define the disease was the most significant contributor identified to the high interstudy heterogeneity (I2 = 98%). Studies using provider/clinician diagnosis instead of laboratory diagnosis reported the lowest incidence, at 3%. The most salient risk factor for TA-TMA reported in 14 studies was preceding acute graft-versus-host disease (GVHD). Other risk predictors described in 5 or more studies included preceding infection, prior transplantation, mismatched donor, and myeloablative conditioning. With a pooled incidence at 12% among a significantly heterogeneous population, TA-TMA is an important but relatively uncommon post-transplantation complication. Given the divergence between reported laboratory-based and provider-based incidence, as well as the multitude of risk factors beyond acute GVHD, future studies should focus on risk-stratifying the subset of TA-TMA patients who would benefit from therapeutic intervention.
Keywords: Bone marrow transplantation; Graft-versus-host disease; TMA; Thrombotic microangiopathies.
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.Clin Transplant. 2018 Sep;32(9):e13371. doi: 10.1111/ctr.13371. Epub 2018 Aug 20. Clin Transplant. 2018. PMID: 30080283
-
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.Transplant Cell Ther. 2023 Mar;29(3):151-163. doi: 10.1016/j.jtct.2022.11.015. Epub 2022 Nov 25. Transplant Cell Ther. 2023. PMID: 36442770 Free PMC article.
-
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566710
-
Risk factors for transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis.Expert Rev Hematol. 2023 Mar;16(3):191-203. doi: 10.1080/17474086.2023.2162501. Epub 2023 Jan 2. Expert Rev Hematol. 2023. PMID: 36588482
-
Neurological involvement in hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Ann Hematol. 2024 Sep;103(9):3303-3313. doi: 10.1007/s00277-024-05798-6. Epub 2024 May 20. Ann Hematol. 2024. PMID: 38763940 Free PMC article. Review.
Cited by
-
Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy.Res Pract Thromb Haemost. 2024 Jul 22;8(5):102517. doi: 10.1016/j.rpth.2024.102517. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39247211 Free PMC article.
-
Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill.Curr Issues Mol Biol. 2024 May 15;46(5):4787-4802. doi: 10.3390/cimb46050288. Curr Issues Mol Biol. 2024. PMID: 38785556 Free PMC article. Review.
-
Transplant-associated TMA: the conundrum of diagnosis and treatment.Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):206-213. doi: 10.1182/hematology.2024000545. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39644048 Free PMC article. Review.
-
Prospective Clinical and Biomarker Validation of the American Society for Transplantation and Cellular Therapy Consensus Definition for Transplantation-Associated Thrombotic Microangiopathy.Transplant Cell Ther. 2023 Nov;29(11):685.e1-685.e7. doi: 10.1016/j.jtct.2023.08.015. Epub 2023 Aug 18. Transplant Cell Ther. 2023. PMID: 37597686 Free PMC article.
-
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.Pharmaceuticals (Basel). 2022 Jul 9;15(7):845. doi: 10.3390/ph15070845. Pharmaceuticals (Basel). 2022. PMID: 35890144 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources